Close menu




Pharma

Photo credits: pixabay.com

Commented by Fabian Lorenz on February 12th, 2025 | 07:00 CET

Analysts on the TUI CRASH! Bayer to make millions! dynaCERT stock is set to skyrocket!

  • Hydrogen
  • greenhydrogen
  • Travel
  • Pharma

Will the dynaCERT stock see a breakthrough soon? The odds are looking good. In an analyst interview, the top German manager cites an increase in revenue, sales, and earnings as a clear goal for the next 12 months. In that case, the stock would currently be a bargain. The TUI share, however, does not appear to be a bargain for investors. The quarterly figures led to a sell-off yesterday. Yet revenue and earnings were in line with expectations. What do analysts say? Bayer's stock also trended weak yesterday, despite new potential millions in revenue from a drug approval.

Read

Commented by Fabian Lorenz on February 10th, 2025 | 07:30 CET

BIOTECH stocks in RALLY MODE: Valneva, BioNxt Solutions, Evotec – BUY signal or correction?

  • Biotechnology
  • Biotech
  • Pharma

After the 50% rally, the stock of BioNxt Solutions is currently consolidating. However, the next buy signal could be generated soon. There will likely be some exciting announcements this year and perhaps even a strategic partnership. The new R&D site in Munich will likely also attract attention for the innovative biotech company in Germany. After the catastrophic year, things have quieted down for the time being at Evotec. Or is it more that the air has been let out? After all, there is a lot of uncertainty about what skeletons might still be in the closet and how things should continue strategically. The stock market does not like that. In contrast, Valneva has had an impressive rally since mid-January. Last week, there was another big announcement. After 50%, is there more potential with the French company?

Read

Commented by Juliane Zielonka on January 31st, 2025 | 06:55 CET

Vidac Pharma, Bayer AG, Novo Nordisk: Three companies that will shape the pharmaceutical landscape in 2025

  • Biotechnology
  • Biotech
  • Pharma

The pharmaceutical industry is again demonstrating its market power between innovation and risk: Vidac Pharma reports a milestone in colorectal cancer therapy with VDA1275. The combination of the active ingredient with a chemotherapeutic agent achieves a 38.9% tumor reduction in preclinical studies. This synergy effect raises hope for gentler chemotherapy treatments and more innovative approaches. Bayer AG is making waves at the JP Morgan Health Conference with its pharmaceutical pipeline: the prostate cancer drug Nubeqa™ achieves blockbuster status with revenue of EUR 1 billion. In women's health, the first non-hormonal therapy for menopausal symptoms is expected to reach the US market as early as 2025. Novo Nordisk, on the other hand, is threatened with a class-action lawsuit in the billion-dollar market for obesity drugs: the REDEFINE-1 study on the promising drug CagriSema revealed weaknesses in the study design. After the results were made public, the share price fell by 18%. While Vidac Pharma and Bayer impress with precise study results, the Novo Nordisk case shows the fragility of methodological fuzziness. The details.

Read

Commented by André Will-Laudien on January 27th, 2025 | 07:40 CET

Biotech - Here we go! 100% opportunities for Evotec, BioNxt, Bayer, Formycon, and Novo Nordisk!

  • Biotechnology
  • Biotech
  • Pharma

Last week, the DAX 40 index reached a new all-time high of 21,520 points. At first glance, this sounds odd because half of the stocks are languishing at multi-year lows. However, the driving forces are the heavyweights SAP, Siemens, Allianz, Airbus, and Deutsche Telekom. They are pushing the index upward daily, putting ETF fund managers under pressure as they have to adjust the weightings accordingly. However, the more capital flows into the leading stocks, the more investors are looking for lagging stocks that could successfully turn the chart around due to operational turning points. We select a few opportunity stocks.

Read

Commented by Armin Schulz on January 22nd, 2025 | 07:00 CET

Evotec, Vidac Pharma, BioNTech – Profiting from the fight against cancer

  • Biotechnology
  • Biotech
  • Pharma

It has been clear for some time that cancer can affect anyone, and not just since King Charles and Princess Kate made their battles with cancer public. The market is growing, and today, revenues in this area are already in the billions. This is driven by an aging population and increasingly unhealthy lifestyles. The margins for manufacturers of cancer drugs are often in the high double-digit percentage range. It is no wonder that companies are focusing on the fight against cancer. Developing a medication that reliably defeats the disease could result in a genuine blockbuster. In 2023, around USD 223 billion was spent on cancer drugs worldwide. We are looking at three companies striving to cure cancer and claim their share of this lucrative market.

Read

Commented by Armin Schulz on January 21st, 2025 | 07:30 CET

Bayer awakened! BioNxt Solutions, Novo Nordisk – Invest in tomorrow's winners today

  • Biotechnology
  • Biotech
  • Pharma

The economy is at a turning point, as the rapid advancements in artificial intelligence are enabling technological innovations that set new benchmarks. Revolutionary developments are emerging, particularly in the pharmaceutical industry, medical technology, and biotechnology. These sectors not only unlock groundbreaking medical possibilities but also offer significant economic growth potential. Investors who move in early to disruptive technologies or dynamic growth industries can count on attractive returns. But which players are dominating this wave of innovation? And how can you, as an investor, benefit strategically? A closer look is worthwhile.

Read

Commented by Stefan Feulner on January 14th, 2025 | 07:55 CET

Qiagen, Vidac Pharma, and Bayer with groundbreaking news

  • Pharma
  • Biotechnology
  • Biotech

In the years to come, biotechnology will play a central role in solving global challenges. From the development of innovative therapies to sustainable agriculture and biobased industries, biotechnology combines science and technology to make the world more sustainable and efficient. As a driver of growth and innovation, it offers enormous opportunities for companies and investors who want to actively shape the future.

Read

Commented by Armin Schulz on January 8th, 2025 | 07:30 CET

Bayer, First Hydrogen, Volkswagen – Turnaround Candidates for 2025 Under Review

  • Hydrogen
  • Fuelcells
  • Electromobility
  • Pharma

After the year-end portfolio window-dressing in December, the new year starts with the hunt for the right stocks for 2025. Special attention should be given to turnaround candidates, meaning stocks that underperformed last year. These companies have faced challenging times and have often already begun addressing their issues through strategic realignment. Sometimes, market conditions for a sector can improve significantly from one year to the next, and then the stocks of these companies often rise disproportionately. Identifying the right stocks requires thorough research. We look at three potential turnaround candidates.

Read

Commented by André Will-Laudien on January 6th, 2025 | 07:00 CET

Biotech-Rally 2025: Evotec, BioNTech, Vidac Pharma, Pfizer and Bayer are on the buy list

  • Biotechnology
  • Pharma
  • Biotech

For two years, there was almost no movement in the biotech sector. Not even the trend of falling interest rates that began in 2024 could persuade investors to make larger investments. Meanwhile, AI and high-tech stocks continued to perform well, driving the Nasdaq 100 index up by over 30%. However, in the last quarter of 2024, some bombed-out life sciences stocks saw significant markups, and new takeover rumours also began circulating. Whether the sentiment can continue to rise in the coming weeks is something we will explore further. Let's take a closer look at our top picks for 2025.

Read

Commented by Armin Schulz on January 3rd, 2025 | 07:00 CET

D-Wave Quantum, ARI Motors, Bayer – Which stocks should be in the portfolio for 2025?

  • Electromobility
  • Pharma
  • Software
  • Technology

After Google presented its quantum processor, Willow, D-Wave Quantum's shares skyrocketed. The question is how sustainable this increase is and whether quantum computing will be the next big hype after artificial intelligence. For the automotive industry, 2024 was a year to forget. Many automakers are currently struggling with problems. ARI Motors, an electric vehicle manufacturer that has secured a niche for itself, is faring better. Will the entire automotive industry manage a turnaround in the coming year? Bayer's shareholders are also hoping for a turnaround. The share price took a significant hit last year. 2025 is expected to be much better. We take a closer look at the individual stocks.

Read